Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Allogene Therapeutics

Clinical trials sponsored by Allogene Therapeutics, explained in plain language.

Allogene Therapeutics ALLO NASDAQ

Clinical-stage biotech developing allogeneic CAR-T therapies.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 2 Not yet finished but already full! 2 Completed 2 Terminated 1

Experimental CAR t combo trial halted early – only 2 patients enrolled

Disease control Terminated

This study tested whether adding an extra drug (ALLO-647) to standard chemotherapy before a special immune cell treatment (CAR T) could help adults with a hard-to-treat type of lymphoma. Only 2 people joined before the trial was stopped early. The goal was to see if the new combi…

Phase: PHASE2 • Sponsor: Allogene Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 09:09 UTC